Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8736628 | 0.92 | NAAA (0.39) | NAAAEPHX1EPHX2 | |
| SCHEMBL8735246 | 0.92 | NAAA (0.39) | NAAAEPHX1EPHX2 | |
| SCHEMBL28514798 | 0.92 | NAAA (0.39) | NAAAEPHX1EPHX2 | |
| SCHEMBL29169850 | 0.89 | CHRM2 (0.35) | CYP1A2NAAAEPHX1 | |
| SCHEMBL2553560 | 0.86 | NAAA (0.42) | NAAAEPHX1EPHX2 | |
| SCHEMBL28513740 | 0.86 | NAAA (0.40) | NAAAEPHX1EPHX2 | |
| SCHEMBL16398522 | 0.85 | AKR1B1 (0.41) | NAAA | |
| SCHEMBL25429424 | 0.85 | KEAP1 (0.36) | NAAAEPHX1 | |
| SCHEMBL19690668 | 0.85 | NAAA (0.35) | CYP1A2NAAAEPHX1EPHX2 | |
| SCHEMBL12393616 | 0.83 | KEAP1 (0.37) | CYP1A2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332462-B2 | Malodor counteractant compounds | GIVAUDAN SA (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7288507-B2 | Malodor counteractant compounds | GIVAUDAN SA (CH) | 2007-10-30 | — | — | US | disclosed |
| US-20070116655-A1 | MALODOR COUNTERACTANT COMPOUNDS | GIVAUDAN SA (CH) | 2007-05-24 | — | — | US | disclosed |
| US-20060034789-A1 | Malodor counteractant compounds | GIVAUDAN SA (CH) | 2006-02-16 | — | — | US | disclosed |
| US-6610648-B2 | Alkyl 3-phenylprop-2-enoic acid ester derivatives | GIVAUDAN SA (CH) | 2003-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060034789-A1 | Malodor counteractant compounds | MAL2, OR51E2, OPRM1 | CYP1A2 576/4885NAAA 3323/4885EPHX1 858/4885 |
| US-20070116655-A1 | MALODOR COUNTERACTANT COMPOUNDS | MAL2, OR51E2, OPRM1 | CYP1A2 666/4885NAAA 3403/4885EPHX1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.